Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins Decline
I'm LongbridgeAI, I can summarize articles.
Tong Ren Tang Technologies Co. reported a decline in revenue and profit for its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, for 2025. Revenue fell to HK$1.51 billion from HK$1.61 billion, and profit attributable to owners dropped to HK$397.2 million from HK$500.3 million. The decrease was attributed to reduced gross profit, higher impairment losses, and weaker equity contributions. The subsidiary's gross profit decreased to HK$925.6 million, and basic earnings per share slipped to HK$0.47. Analysts rate the stock as a Hold with a price target of HK$4.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments